20
2019-12
On December 20, 2019, Future Top 100 Medical Enterprises Meeting of 2019 under the theme of “New Life Increment” was kicked off in Beijing· Jiuhua Villa. The meeting focused on multiple factors such as policy environment, technology environment and demanding spaces, provided comprehensive interpretation of the future development trend of health care industry to promote the reform of innovative health care industry.
29
2019-08
How Many Blockbuster Novel Drugs Can Be Produced for Chinese Hair Loss Population of 250 Million?
Recently, a group of data indicating more than 250 million people with hair loss in China has circulated online and caused heated discussion. In fact, hair loss is a common disease worldwide. Under normal circumstances, a healthy person will have nearly a hundred hairs shed naturally every day, and an equal amount of hair will be reborn from the scalp hair follicles. If hair loses faster than growth of newborn hair, there will be hair loss problem, which will affect the aesthetics and mental health.
29
2018-10
Blockbuster news! 2018 Dongsha Lake [Venture Capital] Annual List Came out!
The 2018 Dongsha Lake [Venture Capital] Carnival sponsored by Oriza Holdings was held in Suzhou Industrial Park on October 29. Top fund investors,fund managers,and outstanding entrepreneurs in domestic private equity investment industry gathered in Dongsha Lake Fund Town to discuss the future development of Chinese venture capital industry and share their insights on industry trends and investment logic.
31
2018-07
Dr. Youzhi Tong of Suzhou Kintor: Entering the Spring for Innovative Drug Development
Dr. Youzhi Tong hopes that Suzhou Kintor is not merely a company that only addresses local pharmaceutical needs,but rather a company with a global product layout.
25
2018-06
Suzhou Kintor’s Dr. Youzhi Tong: In the Name of Father
Aspiring to become an academic expert,Dr. Tong accidentally entered the entrepreneurial circle. Under his leadership,Kintor Pharmaceuticals combines independent research and development with external introductions,develops innovative drug Proxalutamide,and works with Pfizer to develop ALK-1 in an attempt to build a leading anti-tumor innovative drug company in China.
09
2017-07
2017 Clinical Summit Forum: Where There Is the Market,There Are Clinical Trials | Primary Scene
Dr.Chuangxing Guo of Suzhou Kintor gave a presentation on the implementation of dual declaration of Proxalutamide in China and the United States at the "2017 China Novel Drugs Clinical Development Summit Forum" sponsored by PharmaDJ.Existing data proves that Proxalutamide has obvious advantages in pharmacological activity compared with other AR antagonists,so it is expected to become the best-in-class among the second-generation new AR antagonists.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn